TY - JOUR
T1 - Outcome after first relapse in children with acute lymphoblastic leukemia
T2 - A report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol
AU - Van den Berg, H.
AU - de Groot-Kruseman, H. A.
AU - Damen-Korbijn, C. M.
AU - de Bont, E. S.J.M.
AU - Schouten-van Meeteren, A. Y.N.
AU - Hoogerbrugge, P. M.
AU - de Groot-Kruseman, Hester
PY - 2011/8
Y1 - 2011/8
N2 - Background: We report on the treatment of children and adolescents with acute lymphoblastic leukemia (ALL) in first relapse. The protocol focused on: (1) Intensive chemotherapy preceding allogeneic stem cell transplantation (SCT) in early bone marrow relapse; (2) Rotational chemotherapy in late relapse, without donor; (3) Postponement of cerebro-spinal irradiation in late isolated CNS relapse; and (4) Treatment in very late bone marrow relapse with chemotherapy only. Methods: From January 1999 until July 2006 all 158 Dutch pediatric patients with ALL in first relapse were recorded. Ninety-nine patients were eligible; 54 patients with early and 45 with late relapse. Eighteen patients had an isolated extra-medullary relapse; 69 patients had bone marrow involvement only. Results: Five-years EFS rates for early and late relapses were 12% and 35%, respectively. For early relapses 5 years EFSs were 25% for patients transplanted; 0% for non-transplanted patients. For late relapses 5 years EFS was 64% for patients treated with chemotherapy only, and 16% for transplanted patients. For very late relapses EFS was 58%. Conclusions: Our data suggest the superiority of SCT for early relapse patients. For late relapses a better outcome is achieved with chemotherapy only using the rotational chemotherapy scheme. The most important factor for survival was interval between first CR and occurrence of the first relapse.
AB - Background: We report on the treatment of children and adolescents with acute lymphoblastic leukemia (ALL) in first relapse. The protocol focused on: (1) Intensive chemotherapy preceding allogeneic stem cell transplantation (SCT) in early bone marrow relapse; (2) Rotational chemotherapy in late relapse, without donor; (3) Postponement of cerebro-spinal irradiation in late isolated CNS relapse; and (4) Treatment in very late bone marrow relapse with chemotherapy only. Methods: From January 1999 until July 2006 all 158 Dutch pediatric patients with ALL in first relapse were recorded. Ninety-nine patients were eligible; 54 patients with early and 45 with late relapse. Eighteen patients had an isolated extra-medullary relapse; 69 patients had bone marrow involvement only. Results: Five-years EFS rates for early and late relapses were 12% and 35%, respectively. For early relapses 5 years EFSs were 25% for patients transplanted; 0% for non-transplanted patients. For late relapses 5 years EFS was 64% for patients treated with chemotherapy only, and 16% for transplanted patients. For very late relapses EFS was 58%. Conclusions: Our data suggest the superiority of SCT for early relapse patients. For late relapses a better outcome is achieved with chemotherapy only using the rotational chemotherapy scheme. The most important factor for survival was interval between first CR and occurrence of the first relapse.
KW - Acute lymphoblastic leukemia
KW - Central nervous system
KW - Child
KW - Stem cell transplantation
KW - Testicular leukemia
UR - https://www.scopus.com/pages/publications/79958842093
U2 - 10.1002/pbc.22946
DO - 10.1002/pbc.22946
M3 - Article
C2 - 21337680
AN - SCOPUS:79958842093
SN - 1545-5009
VL - 57
SP - 210
EP - 216
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 2
ER -